BiomX Inc. (NYSE:PHGE) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET
Company Participants
Jonathan Eitan Solomon – CEO & Director
Marina Wolfson – CFO & Secretary
Conference Call Participants
I-Eh Jen – Laidlaw & Company (UK) Ltd., Research Division
Joseph Pantginis – H.C. Wainwright & Co, LLC, Research Division
Operator
Good morning, and welcome to the BiomX Second Quarter 2025 Financial Results and Business and Program Update Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
I would now like to turn the call over to Marina Wolfson, Chief Financial Officer of BiomX. Please proceed.
Marina Wolfson
Thank you, and welcome to the BiomX conference call to review the company’s second quarter 2025 financial results and provide an update on our business and programs. Later today, we will file the quarterly report on Form 10-Q with the Securities and Exchange Commission.
In addition, the press release became available at 6:30 a.m. Eastern Time today and can be found on our website at biomx.com. A replay of this call will also be available on the Investors section of our website. As we begin, I’d like to review the safe harbor provision.
All statements on this call that are not factual historic statements may be deemed forward-looking statements. For instance, we’re using forward-looking statements when we discuss on the conference call, the sufficiency of the company’s cash, our pipeline, momentum and milestones, the design, recruitment, aim, expected timing, and interim and final results of our clinical trials, expected feedback from the FDA and additional regulatory agencies and results thereof, the potential benefits of our product candidates, the potential safety or efficacy or product candidates, BX004 and BX211, and the potential markets and partnering opportunities for our product candidates.
In addition, past and current clinical results as
#BiomX #PHGE #Earnings #Call #Transcript